CytRx Corporation

CytRx Corporation (NASDAQ: CYTR), is a biopharmaceutical company specializing in oncology.  CytRx also maintains a 36% equity interest in RXi Pharmaceuticals (Nasdaq: RXII).
 

About CytRx Corp >
News & Events >
Investor Relations >
Careers >
Contact Us >

Development Pipeline

CytRx's drug development pipeline includes programs in Phase 2 clinical development for numerous cancer indications. CytRx recently announced plans to initiate Phase 2 trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas, and a Phase 2 proof-of-concept clinical trial with bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL). CytRx's pipeline also includes tamibarotene, which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL), and CytRx is developing two drug candidates based on the its proprietary molecular chaperone technology which aims to repair or degrade misfolded proteins associated with disease.

Oncology Portfolio >

Molecular Chaperone Regulation > 

News & Events

03/08/10 CytRx to Present at the Roth Capital Partners OC Growth Stock Conference More>>>
 

02/01/10 CytRx to Present at the 12th Annual BIO CEO & Investor Conference More>>>
 

01/21/10 CytRx Announces 2010 Clinical and Development Milestones More>>> 
 

See more press releases >>>